RedHill Biopharma

Company Overview

Snapshot

Founded in August 2009 by Dror Ben-Asher, RedHill Biopharma operates with 11–50 employees. The company has raised over $307.15 million across 23 funding rounds from 14 investors. In October 2025, RedHill Biopharma secured a strategic investment and co-commercialization partnership deal for its drug Talicia, which included a $4 million investment from.

Business overview

RedHill Biopharma is a biopharmaceutical company focused on developing and commercializing proprietary drugs for gastrointestinal and infectious diseases. The company's core products include the FDA-approved drugs Talicia and Aemcolo, which are promoted in the U.S. by a dedicated sales team. RedHill Biopharma also maintains an advanced R&D pipeline of late-stage clinical development drug candidates addressing significant unmet medical needs within the pharmaceuticals and healthcare sectors.

Strategic signal

In September 2024, RedHill Biopharma's drug Talicia was listed as a first-line choice for H. pylori in new American College of Gastroenterology guidelines. This endorsement signals strong clinical validation and market acceptance for Talicia, potentially driving increased adoption and revenue for the company in the gastroenterology market.

Company Intelligence Q&A

What was a significant recent financial development for RedHill Biopharma?

In October 2025, RedHill Biopharma secured a strategic investment and U.S. co-commercialization partnership deal for its drug Talicia, which included a $4 million investment from.

What is the latest regulatory update for Talicia?

In September 2024, RedHill Biopharma's Talicia was listed as a first-line choice for H. pylori in new American College of Gastroenterology guidelines.

What is the status of RedHill Biopharma's compliance with Nasdaq listing requirements?

In September 2024, RedHill Biopharma regained compliance with the Nasdaq minimum bid price requirement.

Did RedHill Biopharma secure any recent intellectual property for its drugs?

In September 2023, RedHill announced a new USPTO Notice of Patent Allowance for Opaganib and an EU patent grant for RHB-102 (BEKINDA®).

What was the outcome of the New York Supreme Court appeal involving RedHill Biopharma?

In September 2025, the New York Supreme Court upheld its original summary judgment ruling in favor of RedHill Biopharma, dismissing an appeal and upholding a $10 million summary judgment against Kukbo.